Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

Patent metadata

Field	Value
Publication number	US-11160887-B2
Application number	US-201916267477-A
Country	US
Kind code	B2
Filing date	Feb 5, 2019
Priority date	Jan 10, 2008
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

First claim

The invention claimed is:

1. A compound of the chemical structure:
(Y) q —X m -(ABC) n -Cycpeptide

Wherein Y is a chelate group, said chelate group incorporating or complexing with a radioisotope;
Each X is independently an amino acid linker

ABC is an amino acid linker wherein
A is absent or is a neutral or negatively charged amino acid at physiological pH;
B is a neutral or negatively charged amino acid at physiological pH;
C is absent or is a neutral or negatively charged amino acid at physiological pH;
m is 0 or 1;
n is 0 or 1;
p is an integer from 0 to 20;
q is 1, and
Cycpeptide is a cyclic peptide having a formula:
c[Lys-(X)-Glu-His-(Y b )-Arg-Trp-(Z))-Arg-Pro-W-T]

Wherein X is norleucine (Nle), leucine or isoleucine;
Y b is D-phenylalanine or L-phenylalanine;
Z is glycine or alanine;
W is valine, leucine or isoleucine;
T is aspartic acid, glutamic acid or a

Where Z is an amino acid residue or an amino acid linker according to

j is 0, 1 or 2;
r is an integer from 0 to 5;
s is 1;
w is 0 to 20; or
a pharmaceutically acceptable salt thereof,
wherein said radioisotope is selected from the group consisting of 86 Y, 90 Y, 111 In, 177 Lu, 225 Ac, 212 Bi, 213 Bi, 66 Ga, 67 Ga, 68 Ga, 64 Cu, 67 Cu, 71 As, 72 As, 76 As, 77 As, 65 Zn, 48 V, 203 Pb, 209 Pb, 212 Pb, 166 Ho, 149 Pm, 153 Sm, 201 Tl, 188 Re, 186 Re and 99m Tc.

2. The compound according to claim 1 wherein said radioisotope is polycationic.

3. The compound according to claim 1 wherein n is 1.

4. The compound according to claiml, wherein j is 1, r is 1 to 5 and w is 2 to 8.

5. The compound according to claim 1 wherein q is 1, m is 0, n is 1, j is 1 and T is aspartic acid or glutamic acid.

6. The compound according to claim 1 wherein Y is a radical of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 4,11-bis(carboxymethyl)-1, 4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), Diethylenetriaminopentaacetic acid (DTPA), Mercaptoacetyltriglycine (MAG 3 ) or 4,5-bis(2-mercaptoacetamido)pentanoic acid.

7. The compound according to claim 1 wherein Y is a radical of DOTA.

8. The compound according to claim 1 wherein q is 0, W is valine, X is norleucine, Y b is D-phenylalanine, Z is glycine and T is a

Where Z is an amino acid residue or an amino acid linker according to

j is 0, 1 or 2;
r is an integer from 0 to 5;
s is 1;
w is 0 to 20; and
Y is complexed with said radioisotope.

9. The compound according to claim 8 wherein j is 1, r is 0 or 1; and w is 2 to 8.

10. The compound according to claim 8 wherein Y is a radical of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 4,11-bis(carboxymethyl)-1, 4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), Diethylenetriaminopentaacetic acid (DTPA), Mercaptoacetyltriglycine (MAG 3 ) or 4,5-bis(2-mercaptoacetamido)pentanoic acid.

11. The compound according to claim 8 wherein m is 0.

12. The compound according to claim 8 wherein n is 1 .

13. The compound according to claim 8 wherein r is 0.

14. The compound according to claim 8 wherein m is 0 and n is 1.

15. The compound according to claim 8 wherein m is 0, n is 1 and A is absent.

16. The compound according to claim 8 wherein A is glycine, glutamic acid or aspartic acid, B is glutamic acid or aspartic acid and C is absent.

17. The compound according to claim 1 wherein said radioisotope is selected from the group consisting of 111 In, 86 Y, 66 Ga, 68 Ga, 203 Pb, 64 Cu and 99m Tc, 90 Y, 177 Lu, 186 Re, 188 Re, 212 Bi/ 212 Pb, 213 Bi, 149 Pm, 166 Ho and 153 Sm.

18. A pharmaceutical composition comprising an effective amount of a compound comprising a radioisotope according to claim 1 in combination with a pharmaceutically acceptable carrier, additive or excipient.

19. The composition according to claim 18 wherein said compound is combined with at least one agent selected from the group consisting of dacarbazine (DTIC), interleukin-2 (IL-2) and α-interferon.

20. A method of diagnosing the existence or absence of melanoma in a patient at risk for melanoma comprising administering to said patient a compound according to claim 1 ; imaging said patient to determine if tissue in said patient exhibits elevated expression of MSH receptors; and diagnosing said patient as having melanoma if said tissue evidences elevated expression of MSH receptors in comparison to a standard.

21. A method of treating melanoma in a patient in need of therapy comprising administration to said patient an effective amount a composition according to claim 18 .

22. The method according to claim 21 wherein said compound is coadministered with an effective amount of at least one agent selected from the group consisting of dacarbazine (DTIC), interleukin-2 (IL-2) and α-interferon.

23. A method of monitoring therapy of a patient in the treatment of melanoma, said method comprising administering to a patient undergoing melanoma treatment an imaging effective amount of a compound according to claim 1 , imaging said patient to determine if tissue in said patient exhibits elevated expression of MSH receptors; and comparing the results of said imaging step with a standard.

Assignees

• Unm Rainforest Innovations

Inventors

• Miao Yubin
• Guo Haixun

Classifications

• G01N33/5751

  of the skin, e.g. melanoma · CPC title

• C07K14/685 Primary

  Alpha-melanotropin · CPC title

• G01N33/60

  involving radioactive labelled substances · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title